How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?-Reference-Cited by-同舟云学术

How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?

Published:2022-09-20 Issue:11 Volume:40 Page:2667-2673
ISSN:1433-8726
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Fallara Giuseppe^ORCID,Larcher Alessandro,Rosiello Giuseppe,Raggi Daniele,Marandino Laura,Martini Alberto,Basile Giuseppe,Colandrea Gianmarco,Cignoli Daniele,Belladelli Federico,Re Chiara,Musso Giacomo,Cei Francesco,Bertini Roberto,Briganti Alberto,Salonia Andrea,Montorsi Francesco,Necchi Andrea,Capitanio Umberto

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

https://link.springer.com/content/pdf/10.1007/s00345-022-04153-6.pdf

Reference23 articles.

1. Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang Y-H et al (2021) Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. New Engl J Med 385:683–694. https://doi.org/10.1056/nejmoa2106391

2. Network NCC (n.d.) Kidney Cancer Version 4.2022. https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf (accessed Decr 26, 2021).

3. Powles T, Albiges L, Bex A, Grünwald V, Porta C, Procopio G et al (2021) ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol 32:1511–1519. https://doi.org/10.1016/j.annonc.2021.09.014

4. Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Lam TB et al (2021) 2021 Updated European Association of Urology guidelines on the use of adjuvant pembrolizumab for renal cell carcinoma. Eur Urol 81:134–137. https://doi.org/10.1016/j.eururo.2021.11.022

5. Capitanio U, Montorsi F (2016) Renal cancer. Lancet 387:894–906. https://doi.org/10.1016/s0140-6736(15)00046-x

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognostic role of histomorphological subtyping in nonmetastatic papillary renal cell carcinoma after curative surgery: is subtype really irrelevant? A propensity score matching analysis of a multi-institutional real life data;Urologic Oncology: Seminars and Original Investigations;2024-05

2. Assessing the impact of lymphovascular invasion on overall survival in surgically treated renal cell carcinoma patients: A nationwide cohort analysis;Urologic Oncology: Seminars and Original Investigations;2023-10

3. Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?;European Urology Open Science;2022-12